GlobeNewswire Inc | Oct 20, 2020 04:15PM EDT

October 20, 2020

WALTHAM, Mass., Oct. 20, 2020 (GLOBE NEWSWIRE) -- Radius Health (Nasdaq: RDUS) announced today that it will release its third quarter financial results on Thursday, November 5, 2020. The Company will host a conference call and live audio webcast at 8:30 a.m. ET that day to discuss the results and provide a company update.

Conference Call Information: Domestic Dial-In Number: (866) 323-7965International Dial-In Number: (346) 406-0961Conference ID: 9147422

A replay of the conference call will be available on November 5 at 11:30 a.m. ET and live audio webcast of the call will be archived on the Company's website for ninety days. To access the replay, dial (855) 859-2056 U.S. or (404) 537-3406 for International, using conference ID number 9147422. The live audio webcast of the call can be accessed from the Investors section of the Companys website, https://ir.radiuspharm.com/events-and-presentations. The full text of the announcement and financial results will also be available on the Companys website.

About Radius

Radius is a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative endocrine therapeutics. Radius lead product, TYMLOS (abaloparatide) injection, was approved by the U.S. Food and Drug Administration for the treatment of postmenopausal women with osteoporosis at high risk for fracture. The Radius clinical pipeline includes the investigational use of abaloparatide injection for the treatment of men with osteoporosis, an investigational abaloparatide-patch for potential use in osteoporosis and the investigational drug elacestrant (RAD1901) for potential use in hormone-receptor positive breast cancer out-licensed to Menarini Group. For more information, please visitwww.radiuspharm.com

Investor & Media Relations Contact:Elhan Webb, CFAEmail: ewebb@radiuspharm.comPhone: 617-551-4011